Welcome to our dedicated page for CHEMED SEC filings (Ticker: CHE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Chemed Corporation filings document a Delaware operating company whose capital stock trades on the NYSE under CHE and whose business is conducted through VITAS Healthcare and Roto-Rooter. Current reports disclose segment operating results for hospice and palliative care services, plumbing and drain cleaning services, patient-care metrics, service revenue and capital allocation.
Chemed's regulatory record also includes 8-K disclosures for earnings releases, Regulation FD updates, senior secured revolving credit facilities and related direct financial obligations. Proxy materials cover director elections, executive compensation, pay-versus-performance data and governance matters, while event reports record leadership changes within the VITAS business.
Chemed Corporation president and CEO Kevin J. McNamara completed an open-market sale of company Capital Stock. On March 27, 2026, he sold 1,500 shares at a weighted average price of $369.37 per share in multiple trades.
The shares were sold at prices ranging from $365.76 to $373.24. Following this transaction, McNamara directly holds 92,219 shares of Chemed stock.
Chemed Corporation filed a Form 144 notifying a proposed sale of 1,500 shares of Common stock. The notice lists Merrill Lynch as the broker and an effective filing date of 03/27/2026. The filing also records two reported sales by Kevin McNamara of 1,000 shares each on 03/12/2026.
Chemed Corp (CHE) Schedule 13G/A amendment reports that The Vanguard Group holds 0 shares of Chemed common stock, representing 0% of the class as disclosed in the filing dated 03/13/2026. The filing explains an internal realignment at Vanguard on 01/12/2026 that caused disaggregated reporting by subsidiaries; no beneficial ownership is claimed here.
CHEMED CORP president and CEO Kevin J. McNamara sold 2,000 shares of Capital Stock in an open-market transaction at a weighted average price of $403.18 per share. Following this sale, he directly holds 93,719 shares. The trade was executed through multiple transactions at prices between $399.31 and $404.68.
Chemed Corporation reports a Form 144 notice reflecting proposed sales of Common Stock by Kevin McNamara related to stock awards and exercises. The filing lists award/exercise events dated 02/17/2023, 05/01/2023, and 05/02/2023, including awards of 492 and 498 shares.
Chemed Corporation operates two main businesses: VITAS hospice and palliative care and Roto-Rooter plumbing and restoration services, all managed in a decentralized structure. VITAS generates over 95% of its revenue from Medicare and Medicaid per-diem payments, making government reimbursement policies critical to its results.
The filing highlights extensive regulatory oversight, including hospice Conditions of Participation, anti-kickback and false-claims rules, licensing and Certificate of Need laws, and evolving privacy and cybersecurity requirements. VITAS previously operated under a five-year corporate integrity agreement that concluded in 2023, and in 2025 experienced a cyberattack in which a threat actor accessed protected health information.
Roto-Rooter faces fragmented but intense competition and is sensitive to weather-driven demand and labor availability for licensed plumbers. As of December 31, 2025, Chemed employed 15,811 people and emphasized safety, training and retention programs. Recent growth initiatives included multiple small Roto-Rooter franchise purchases and VITAS’s $85.0 million cash acquisition of Covenant hospice operations and an assisted living facility.
Chemed Corporation reported mixed fourth-quarter 2025 results and issued 2026 guidance. Q4 service revenues and sales were $639.3 million, essentially flat year over year, while net income declined to $76.8 million from $90.3 million. Diluted EPS fell to $5.48 from $6.02.
VITAS net revenue grew 1.9% to $418.8 million, supported by higher days-of-care and Medicare reimbursement, though gross margin excluding Medicare Cap fell to 27.3%. Roto-Rooter revenue declined 3.7% to $220.6 million, and adjusted EBITDA dropped 21.1% with margin down to 21.5%.
For full-year 2025, Chemed generated service revenues and sales of $2.53 billion and net income of $265.2 million, or $18.34 diluted EPS. Adjusted diluted EPS was $21.55. The company ended 2025 with $74.5 million in cash, no debt, and repurchased 400,000 shares for $174.6 million.
Management expects 2026 VITAS revenue to grow 5.5%–6.5% before Medicare Cap and Roto-Rooter revenue to grow 3.0%–3.5%. Adjusted diluted EPS is projected between $23.25 and $24.25, above 2025’s $21.55, with about 55% of adjusted earnings and EBITDA weighted to the year’s second half.
Chemed Corp executive vice president Spencer S. Lee reported PSU vesting, share issuance, tax withholding, and a new equity award. On February 13, 2026, 499 shares of Chemed capital stock were acquired through derivative exercises at $469.56 per share, with 154 shares withheld to cover taxes, leaving 14,912 shares of capital stock held directly.
Two tranches of 402 performance stock units each were exercised at $0, with 1,966 and 1,564 PSUs remaining after the respective transactions. Lee also received a new grant of 960 PSUs, bringing direct PSU holdings to 2,524. One PSU award tied to cumulative adjusted EPS paid out at 124.1% of target based on $67.67 performance versus a $66.46 maximum threshold, while a separate PSU award tied to relative total shareholder return paid out at 0% of target.
Chemed vice president and director Thomas C. Hutton reported equity compensation activity, not open-market trading. On February 13, 2026, he exercised performance stock units (PSUs) into 199 shares of capital stock at $469.56 per share and had 72 shares withheld to cover tax obligations tied to vesting.
The PSUs that vested were based on Chemed’s cumulative adjusted earnings per share from January 1, 2023 through December 31, 2025, where actual performance of $67.67 exceeded the maximum payout threshold of $66.46, producing an award above target. A separate PSU tranche tied to relative total shareholder return over the same period paid out at 0% of target. Hutton also received a new grant of 374 PSUs that can vest over the 2026–2028 performance period.